Drug Profile
Davunetide intranasal
Alternative Names: AL-108; NAP; NAPVSIPQLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator National Institutes of Health (USA); Tel Aviv University
- Developer Allon Therapeutics
- Class Antidementias; Eye disorder therapies; Neuropeptides; Neuroprotectants; Nootropics
- Mechanism of Action Microtubule-associated protein modulators; Tau protein inhibitors; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Alzheimer's disease; Mild cognitive impairment; Schizophrenia
Highest Development Phases
- Discontinued Alzheimer's disease; Mild cognitive impairment; Parkinson's disease; Progressive supranuclear palsy; Schizophrenia
Most Recent Events
- 16 Jul 2013 Allon Therapeutics has been acquired by Paladin Labs
- 18 Dec 2012 Efficacy data from a phase II/III clinical trial in Progressive supranuclear palsy released by Allon Therapeutics
- 31 May 2012 Data Safety Monitoring Board recommends phase II/III trial in Progressive supranuclear palsy continue under existing protocol